Peginterferon Alfa-2a and Ribavirin and Ribavirin in Hepatitis C and Thalassemia - Clinical Trials Registry

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hepatitis C is an inflammation of the liver that is caused by infection with the hepatitis C virus. Over time, people may develop liver failure, liver cancer, or cirrhosis, a condition in which the liver may become permanently scarred. Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C. Ribavirin stops the hepatitis C virus from spreading inside the body, and peginterferon alfa-2a decreases the amount of hepatitis C virus in the body. Individuals with thalassemia, an inherited blood disorder that can cause anemia, often receive regular blood transfusions as part of their treatment. These individuals may have an increased risk of developing hepatitis C as a result of blood transfusions received before routine hepatitis C blood screening was available. Treating thalassemia patients with standard hepatitis C therapy can be difficult because ribavirin can worsen anemia. However, omitting ribavirin then increases the risk of hepatitis C relapse following treatment. The purpose of this study is to evaluate the safety of ribavirin and peginterferon alfa-2a for treating hepatitis C in adults with thalassemia.

This study will enroll adults with thalassemia and long-term hepatitis C. Participants will attend study visits weekly for 4 weeks, every 2 weeks until Week 24, every 4 weeks until Week 48, and then every 6 weeks until Week 72. All participants will receive a peginterferon alfa-2a injection once a week and ribavirin daily. Participants with the hepatitis C genotype 1 will receive 48 weeks of treatment; participants with all other genotypes of the disease will receive 24 weeks of treatment. A liver biopsy will occur at baseline and Week 48. The following will occur at selected study visits: physical exam, blood and urine collection, hearing and vision screening, chest x-ray, heart rate monitoring, and questionnaires to assess hepatitis C symptoms, quality of life, and depression. Participants with liver iron levels greater than 20 mg/g will undergo an echocardiogram ultrasound test every 3 months to monitor the heart.

Study Type

Interventional

Enrollment (Actual)

21

Phase

Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Canada
- Ontario
  - Toronto, Ontario, Canada, M5G 2C4
    - Toronto General Hospital, Universty Health Network
United Kingdom
- - London, United Kingdom, WC1E 6HX
    - University College London
United States
- California
  - Oakland, California, United States, 94609
    - Children's Hospital and Research Center at Oakland
- New York
  - New York, New York, United States, 10021
    - Weill Medical College of Cornell University
- Pennsylvania
  - Philadelphia, Pennsylvania, United States, 19104
    - Children's Hospital Philadelphia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 44 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Diagnosis of thalassemia
Serum positive for hepatitis C virus RNA by polymerase chain reaction (PCR) test (using the Roche COBAS Amplicor hepatitis C virus test)
Hepatitis B surface antigen (HBsAg) negative and HIV negative within the 12 months prior to study entry
Liver biopsy showing histologic evidence of active hepatitis (i.e., at least grade 1 inflammation)
Willing to use acceptable forms of contraception throughout the study

Exclusion Criteria:

Baseline liver iron concentration greater than 40.00 mg/g dry weight (iron may be chelated and the individual re-screened). All people with liver iron levels greater than 20.00 mg/g dry weight will be permitted to enroll only if their ejection fraction is 55 or greater by echocardiography (ECHO).
Currently participating in other interventional clinical studies
Received interferon-alfa therapy within the 6 months prior to study entry
Liver dysfunction, defined as international normalized ratio (INR) greater than 1.3, albumin less than or equal to 3.5g/dL, or serum bilirubin greater than 4.0 mg/dL that, in the opinion of the investigator, is not due to Gilbert's syndrome or thalassemia-related hemolysis
Other causes of liver disease (e.g., hereditary hemochromatosis, presumed drug-associated liver disease, Wilson's disease, obesity [body mass index (BMI) greater than 30])
Major psychiatric illness
Neutrophil count less than or equal to 1500/mm3
Platelet count less than or equal to 80,000/mm3
Active alcohol abuse within the 12 months prior to study entry
Use of illicit drugs (e.g., heroin, cocaine, angel dust) within the 2 years prior to study entry
Alpha-fetoprotein level greater than 200 ng/mL or evidence of a liver mass lesion by either ultrasound, CT scan, or MRI scan that is suspicious for hepatocellular cancer
Kidney insufficiency, as defined by a clinically significant abnormal serum creatinine test and confirmed by a creatinine clearance rate of less than 50 mL/min based on 24-hour urine collection. People with an elevated serum creatinine level must undergo a creatinine clearance test.
Diabetes that, in the opinion of the investigator, is not controlled by diet, an oral hypoglycemic agent, and/or insulin
Received an organ, limb, or bone marrow transplant
Requires the use of certain long-term medications such as immunosuppressive medications (e.g., corticosteroids, methotrexate, azathioprine)
Active systemic autoimmune disorder (e.g., rheumatoid arthritis, systemic lupus)
Diagnosis or treatment of cancer within the 5 years prior to study entry, except for localized squamous or basal cell cancers treated by local excision
Any of the following pre-existing conditions that, in the opinion of the investigator, would prevent treatment with interferon and/or ribavirin:
1. unstable heart disease that is not controlled by medication
2. serious cerebrovascular disease
3. serious lung disease
History of a seizure disorder that has not been well-controlled by anti-seizure medications within the 2 years prior to study entry
Pregnant or breastfeeding
Male partners of women who are pregnant
Any other condition that, in the opinion of the investigator, would prevent study participation
Known hypersensitivity to any study drug or their components
Past history of multiple sclerosis, transverse myelitis, optic neuritis, papilledema, chorioretinitis, uveitis, or increased ocular pressure/glaucoma
Currently taking hematopoietic growth factors
Currently taking ribavirin

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Interventional Model: Single Group Assignment
Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications) Time Frame: Measured at Week 72	Measured at Week 72

Secondary Outcome Measures

Outcome Measure	Time Frame
Mean change in hepatic iron concentration from baseline biopsy to follow-up biopsy; relationship of change to baseline level Time Frame: Measured at Week 48	Measured at Week 48
Transfusion frequency and volume required to maintain trough Hb 9.0-10.5 g/dL during treatment, as compared to that required in the 6 months prior to hepatitis C treatment Time Frame: Measured at Week 72	Measured at Week 72
Cumulate change in deferoxamine dose; evidence for deferoxamine toxicity during hepatitis C treatment Time Frame: Measured at Week 72	Measured at Week 72
Response rate (undetectable hepatitis C virus RNA) Time Frame: Measured at Week 24 or 48	Measured at Week 24 or 48
Sustained virologic response rate (undetectable hepatitis C virus RNA 24 weeks after the end of treatment) and its association with baseline hepatic iron concentration Time Frame: Measured at Week 72	Measured at Week 72
Rate of viral clearance from serum in the first 4 weeks of treatment, rate of early virologic response at week 12, and each rate's association with sustained virologic response Time Frame: Measured at Week 72	Measured at Week 72
Change in liver inflammation and fibrosis scores from baseline to 48 weeks Time Frame: Measured at Week 48	Measured at Week 48
Adverse events Time Frame: Measured at Week 72	Measured at Week 72
Cardiac adverse events, defined as either symptomatic left ventricular dysfunction requiring medication or pathologic arrhythmia requiring medication Time Frame: Measured at Week 72	Measured at Week 72
Quality of life Time Frame: Measured at Week 72	Measured at Week 72

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

HealthCore-NERI

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Study Chair: Maureen Jonas, MD, Boston Children's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2003

Primary Completion (Actual)

June 1, 2006

Study Completion (Actual)

August 1, 2006

Study Registration Dates

First Submitted

July 16, 2007

First Submitted That Met QC Criteria